DOCSLIB.ORG

Active Pharmaceutical Ingredient (API) CAS Number 1,4 Butanediol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Active Pharmaceutical Ingredient (API) CAS Number 1,4 Butanediol Sh ee t1 Active Pharmaceutical Ingredient (API) CAS Number 1,4 Butanediol dimethanesulfonate 55-98-1 2’-DEOXY-L-THYMIDINE 3424-98-4 2-Bromoethyl Methyl Ether 6482-24-2 9-cis-Retinoic Acid 5300-03-8 Abagovomab 792921-10-9 Abiraterone acetate 154229-18-2 acadesine 2627-69-2 Acamprosate Calcium 121268-17-5 Acamprosate Calcium 77337-73-6 Aceclofenac 89796-99-6 Acenocoumarol 152-72-7 Acephylline Piperazine 18833-13-1 Acetoguanamine 542-02-9 Aciclovir 59277-89-3 Acitretin 55079-83-9 Aclidinium Bromide 320345-99-1 Actinomycin D 50-76-0 Acyclovir sodium 69657-51-8 Adapalene 106685-40-9 Adapalene, micronized 106685-40-9 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 AEE788 497839-62-0 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 AFP-464 (free base) 468719-52-0 AFP-464 (monomethansul) 468719-53-1 AG-014699 459868-92-9 AG-024322 837364-57-5 AG13958 319460-94-1 AG-1478 153436-53-4 AG-490 (Tyrphostin AG490) 133550-30-8 Agatolimod 207623-20-9 Agomelatine 138112-76-2 AICAR 4298-08-2 AKR-501 570406-98-3 Akt-I-1 473382-39-7 Akt-I-1,2 473382-48-8 Alacizumab Pegol 934216-54-3 Alarelin Acetate 79561-22-1 Page 1 Sheet1 Albiglutide 782500-75-8 Albinterferon Alfa-2b 472960-22-8 Alcaftadine 147084-10-4 Aleglitazar 475479-34-6 Alendronate Sodium 121268-17-5 Aleplasinin 481629-87-2 Alferminogene Tadenovec 473553-86-5 Algestone Acetophenide 24356-94-3 Alginic Acid 9005-32-7 Alibendol 26750-81-2 Alipogene Tiparvovec 929881-05-0 Aliskiren hemifumarate 173334-58-2 Allantoin 97-59-6 Allopurinol 315-30-0 Almitrine Dimesylate 29608-49-9 Almorexant 871224-64-5 Alogliptin 850649-61-5 Alogliptin Benzoate 850649-62-6 Alosetron 122852-42-0 Alpha Lipoic Acid 1077-28-7 Aluminium-magnesium-hydroxy-carbonate-hexahydrate 21645-51-2 Alvespimycin 467214-20-6 Alvimopan 156053-89-3 Alvocidib (HCl salt) 131740-09-5 Alvocidib (free base) 146426-40-6 Ambroxol Hydrochloride 23828-92-4 AMG208 1002304-34-8 Amibegron 121524-08-1 Amidopyrine 58-15-1 Amifampridine 54-96-6 AmilorideHCL 17440-83-4 Aminophylline 317-34-0 Amiodarone Hcl 1951-25-3 Amiodaronum Hydrochloride 19774-82-4 Amisulpride 71675-85-9 Amitriptyline 50-48-6 Amitriptyline HCl 549-18-8 Amlodipine Besylate 111470-99-6 Amlodipine Maleate & Succinate 88150-42-9 Ammonium Lactate Solution 515-98-0 Amodiaquine Base 86-42-0 Page 2 Sheet1 Amodiaquine Hydrochloride 69-44-3 Amolimogene Bepiplasmid 870524-46-2 Amonafide dihydrochloride 69408-81-7 Amoxicillin 26787-78-0 Amoxicillin Trihydrate 61336-70-7 Amoxycillin sodium sterile BP98 34642-77-8 Amphotericin B (oral) 1397-89-3 Ampicillin sodium 69-52-3 Ampicillin Sodium Sterile 69-52-3 Ampicillin Trihydrate 69-53-4 Amrubicin 110267-81-7 amsilarotene 125973-56-0 Amuvatinib 850879-09-3 Anacetrapib 875446-37-0 Anagrelide hydrochloride 58579-51-4 Analgin 68-89-3 Anamorelin 249921-19-5 Anastrozole 120511-73-1 Anrukinzumab 910649-32-0 Antipyrine 60-80-0 ANV-944 501345-02-4 AP24534 943319-70-8 Apadenoson 250386-15-3 Apaziquone 114560-48-4 Apilimod 541550-19-0 Aplaviroc 461443-59-4 APO-866 658084-64-1 Apremilast 608141-41-9 Aprepitant 170729-80-3 Apricitabine 160707-69-7 Apricoxib 197904-84-0 Arbaclofen Placarbil 847353-30-4 Arbekacin 51025-85-5 Arformoterol tartrate 200815-49-2 Aripiprazole 129722-12-9 Armodafinil 112111-43-0 Arteether 75887-54-6 Arterolane 664338-39-0 Arzoxifene (hydrochloride salt) 182133-27-3 Arzoxifene 182133-25-1 AS-703026, MSC1936369B 1236699-92-5 ASC-J9 917813-54-8 Page 3 Sheet1 Asenapine 65576-45-6 asenapine maleate 85650-56-2 asenapine 65576-45-6 Aspirin Powder,Dc-90% 50-78-2 Astaxanthin 472-61-7 Astaxanthin 3.3% 7542-45-2 AT-7519 844442-38-2 AT7519 HCl 902135-91-5 AT9283 896466-04-9 Atacicept 845264-92-8 Atazanavir 198904-31-3 Atenolol 29122-68-7 Atomoxetine Hcl 83015-26-3 Atomoxetine Hcl 82248-59-7 Atorvastatin 134523-00-5 Atosiban Acetate 90779-69-4 Atracurium 64228-79-1 Atrasentan 173937-91-2 Atropine Sulfate 5908-99-6 AUY-922； AUY922； NVP-AUY-922 747412-49-3 Axitinib 319460-85-0 axitinib 319460-85-0 AZ 960 905586-69-8 AZ-007；Zaleplon 151319-34-5 Azacitidine 320-67-2 Azathioprine 446-86-6 Azathramycin 76801-85-9 AZD-1152 722543-31-9 AZD1152-HQPA 722544-51-6 AZD5438 602306-29-6 AZD6244 606143-52-6 AZD-7762 860352-01-8 AZD-8055； AZD8055； AZD 8055 1009298-09-2 AZD-8330 1204531-17-8 AZD8931 848942-61-0 Azilsartan 147403-03-0 Azilsartan kamedoxomil 863031-24-7 Azilsartan medoxomil 863031-21-4 Azilsartan 147403-03-0 Azithromycin Dihydrate 117772-70-0 Azixa；verubulin 917369-31-4 Azoximer Bromide 892497-01-7 Page 4 Sheet1 Bafetinib 887650-05-7 Bafetinib 859212-16-1 Balamapimod 863029-99-6 balofloxacin 127294-70-6 Balsalazide 82101-18-6 Bambuterol 81732-46-9 Baminercept 909110-25-4 Banoxantrone (AQ4N) 136470-65-0 Batabulin sodium 195533-53-0 Bavituximab 648904-28-3 Beclomethasone Dipropionate 5534-09-8 Bedaquiline,TMC 207 843663-66-1 Bederocin 757942-43-1 Bedoradrine 194785-19-8 Befiradol 208110-64-9 Begacestat 769169-27-9 Belinostat 414864-00-9 Bendamustine (Free base) 16506-27-7 Bendamustine HCl 3543-75-7 Benfotiamine 22457-89-2 Bentamapimod 848344-36-5 Benazepril 86541-74-4 Benzocaine 94-09-7 Benzphetamine Hcl 5411-22-3 Benzydamine HCL 132-69-4 Beperminogene Perplasmid 627861-07-8 Bepotastine 190786-44-8 Beroctocog Alfa 9001-27-8 Berubicin 677017-23-1 Besifloxacin 141388-76-3 Betahistine Dihydrochloride 5579-84-0 Betamethasone 378-44-9 Betamethasone dipropionate 5593-20-4 Betamethasone valerate 2152-44-5 Betrixaban 330942-05-7 Bevasiranib 959961-96-7 Bevirimat 174022-42-5 BEZ235 (NVP-BEZ235) 915019-65-7 BI-2536 755038-02-9 BI-6727 755038-65-4 BI-78D3 883065-90-5 Biapenem(GMP) 120410-24-4 Page 5 Sheet1 BIBF1120 928326-83-4 BIBR1532 321674-73-1 BIBW-2992 439081-18-2 Bicalutamide 90357-06-5 BI-D1870 501437-28-1 BIIB021 848695-25-0 Bimatoprost 155206-00-1 BIO 1211 187735-94-0 Bisacodyl 603-50-9 Bismuth Subgallate 99-26-3 BIX 02189 1094614-85-3 BIX-02188 1094614-84-2 Bleomycin Sulfate 9041-93-4 Bleomycin Sulphate 9041-93-4 BML-210 537034-17-6 BMS 794833 1174046-72-0 BMS-2 888719-03-7 BMS-214662 195987-41-8 BMS-214662 (monoHCl) 195981-08-9 BMS-536924 468740-43-4 BMS-599626 714971-09-2 BMS707035 729607-74-3 BMS-708163 1146699-66-2 BMS777607 1196681-44-3 BN-83495 288628-05-7 Boceprevir 394730-60-0 Bortezomib 179324-69-7 BORTEZOMIB-PINANEDIOL 205393-22-2 Bosutinib 380843-75-4 Brecanavir 313682-08-5 Bremelanotide 189691-06-3 Brinzolamide 138890-62-7 Briobacept 869881-54-9 Brivanib 649735-46-6 Brivanib Alaninate 649735-63-7 Brivaracetam 357336-20-0 Bromexhin Chlorhydrate 611-75-6 Brompheniramine Maleate 980-71-2 Bronopol 52-51-7 BSI-201 (NSC-746045, IND-71677) 160003-66-7 BSI-401 142404-10-2 BTZ043 1161233-85-7 Page 6 Sheet1 Bucelipase Alfa 9026-00-0 Budesonide 51333-22-3 Buprenorphine Hcl 53152-21-9 Bupropion Hcl 31677-93-7 Buserelin 57982-77-1 Buspirone Hcl 33386-08-2 Butabarbital Sodium 143-81-7 Butalbital 77-26-9 Butriptyline hydrochloride 5585-73-9 BX795 702675-74-9 BX912 702674-56-4 Cabazitaxel 183133-96-2 Cabazitaxel 183133-96-2 Cabozantinib 849217-68-1 Caffeine Anhydrous 58-08-2 Calcipotriol 112828-00-9 Calcitonin 47931-85-1 Calcitonin (Salmon) 12/9/9007 Calcium Dobesilate Monohydrate 20123-80-2 Calcium Levulinate 591-64-0 Calcium Stearate 1592-23-0 Calcium Polycarbophil 9003-97-8 Camobucol 216167-92-9 Canagliflozin 842133-18-0 Canagliflozin 842133-18-0 Canakinumab (heavy chain) 402710-25-2 Canakinumab (light chain) 402710-27-4 Capadenoson 544417-40-5 Capecitabine 154361-50-9 Capecitabine (Xeloda) 154361-50-9 Capecitabine 154361-50-9 Capeserod 769901-96-4 Captopril 62571-86-2 Carbamazepine 298-46-4 Carbamazepine 298-46-4 2 Carbamezepin 298-46-4 Carbocistein 638-23-3 Carbonyl Iron 8053-60-9 Carboplatin 41575-94-4 Carfilzomib 868540-17-4 CARIPORIDE 159138-80-4 Cariprazine 839712-12-8 Page 7 Sheet1 Carisbamate 194085-75-1 Carisoprodol 78-44-4 Carmegliptin 813452-18-5 Carprofen 53716-49-7 Carvedilol 72956-09-3 Casopitant 414910-27-3 Caspofungin 162808-62-0 Catramilast 183659-72-5 Catridecacog 606138-08-3 CC-401 395104-30-0 ceclofenac 89796-99-6 Cediranib 288383-20-0 Cefsulodine sodium 52152-93-9 Ceftaroline Fosamil 229016-73-3 Cefuroxime Axetil 64544-07-6 Cefuroxime Sodium sterile 56238-63-2 Celecoxib 169590-42-5 Celivarone 401925-43-7 Cenersen 872847-66-0 CEP-18770 847499-27-8 CEP-7055 402857-58-3 Cephalexin monohydrate 23325-78-2 Cerubidine (Daunorubicin Hydrochloride) 23541-50-6 Cetrizine Dihydrochloride 83881-51-0 Cevipabulin (free base) 849550-05-6 Cevipabulin 852954-81-5 Cevoglitazar 839673-52-8 CF-101 152918-18-8 CHIR-258 405169-16-6 CHIR-99021；CT99021 252917-06-9 CHK2 Inhibitor II 516480-79-8 Chk2 Inhibitor；Chk2 Inhibitor 724708-21-8 Chloramphenicol 56-75-7 Chlorin e6 19660-77-6 Chloroprocaine Hcl 3858-89-7 Chloroquine phosphate 50-63-5 Chlorpheniramine Maleate 113-92-8 Chlorpromazine hydrochloride 69-09-0 Chlorprothixene HCI BP 6469-93-8 Chlortetracycline Hydrochloride 64-72-2 Choline Fenofibrate 62-49-7 Page 8 Sheet1 Choline Fenofibrate 856676-23-8 Choline theophyllinate 4499-40-5 Cholo Phenaramine Maleate (CP Maleate) 113-92-8 Chondroitin Sulfate 39455-18-0 Chondroitin sulfate sodium salt 9082-07-9 Chrysin 480-40-0 CI-1040, PD-184352 212631-79-3 CI-994 112522-64-2 Ciclesonide 141845-82-1 Cilazapril 92077-78-6 Cilostazol 73963-72-1 Cinacalcet Hcl 226256-56-0 Cinacalcet hydrochloride 364782-34-3 Cinaciguat 329773-35-5 Cinchocaine (Dibucaine) HCL 61-12-1 Cinnarizine 298-57-7 Ciprofloxacin 86393-32-0 Ciprofloxacin Base 85721-33-1 Ciprofloxacin Hydrochloride 86483-48-9 Ciprofloxaicin USP 85721-33-1 Cisapride Monohydrate 40064-34-4 Cisatracurium besylate 96946-42-8 Cisplatin 15663-27-1 Citalopram Hbr.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten Et Al
    US00787 1995 B2 (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten et al. (45) Date of Patent: *Jan. 18, 2011 (54) DRUG DELIVERY SYSTEM COMPRISINGA (52) U.S. Cl. ....................................... 514/171; 514/182 TETRAHYDROXYLATED ESTROGEN FOR (58) Field of Classification Search ................. 514/171, USE IN HORMONAL CONTRACEPTION 514f182 See application file for complete search history. (75) Inventors: Evert Johannes Bunschoten, Heesch (NL); Herman Jan Tijmen Coelingh (56) References Cited Bennink, Driebergen (NL); Christian U.S. PATENT DOCUMENTS Franz Holinka, New York, NY (US) 3,440,320 A 4, 1969 Sackler et al. O O 3,797.494. A 3, 1974 Zaffaroni (73) Assignee: Pantarhei Bioscience B.V., Al Zeist 4,460.372 A 7/1984 Campbell et al. (NL) 4,573.996 A 3/1986 Kwiatek et al. 4,624,665 A 1 1/1986 Nuwayser (*) Notice: Subject to any disclaimer, the term of this 4,722,941 A 2f1988 Eckert et al. patent is extended or adjusted under 35 4,762,717 A 8/1988 Crowley, Jr. U.S.C. 154(b) by 1233 days. 4.937,238 A 6, 1990 Lemon 5,063,507 A 1 1/1991 Lindsey et al. This patent is Subject to a terminal dis- 5,130,137 A 7/1992 Crowley, Jr. claimer. 5,211,952 A 5/1993 Spicer et al. 5,223,261 A 6/1993 Nelson et al. 5,340,584 A 8/1994 Spicer et al. (21) Appl. No.: 10/478,357 5,340,585 A 8/1994 Pike et al. 1-1. 5,340,586 A 8, 1994 Pike et al.
    [Show full text]
  • (Trulicity) Pen and the Semaglutide (Ozempic) Pen
    Protocol H9X-MC-B021(b) Crossover Study Comparing Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen NCT03724981 Approval Date: 30-Nov-2018 H9X-MC-B021(b) Clinical Protocol Page 1 Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of dulaglutide (LY2189265), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Dulaglutide (LY2189265) Eli Lilly and Company Indianapolis, Indiana USA 46285 Protocol Electronically Signed and Approved by Lilly on 07 Aug 2018 Amendment (a) Electronically Signed and Approved by Lilly on 11 Sep 2018 Amendment (b) Electronically Signed and Approved by Lilly on date below Approval Date: 30-Nov-2018 GMT LY2189265 H9X-MC-B021(b) Clinical Protocol Page 2 Table of Contents Section Page Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen ............................................................1 Table of Contents........................................................................................................................2 1.
    [Show full text]
  • The Comparison of the Effect Between Alginate-Based Raft-Forming Liquid and Alginate Liquid on Gastroesophageal Reflux Disease and Gastric Ulcer in Rats
    Online - 2455-3891 Vol 10, Issue 12, 2017 Print - 0974-2441 Research Article THE COMPARISON OF THE EFFECT BETWEEN ALGINATE-BASED RAFT-FORMING LIQUID AND ALGINATE LIQUID ON GASTROESOPHAGEAL REFLUX DISEASE AND GASTRIC ULCER IN RATS HAKIM BANGUN1*, ANAYANTI ARIANTO1, RIRIN ASTYA1, GONTAR A SIREGAR2 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Nanomedicine Center, University of Sumatera Utara, Jl. Tri Dharma No. 5, Kampus USU, Medan, Indonesia. 2Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Jl Dr. T. Mansyur No. 5, Kampus USU, Medan, Indonesia. Email: [email protected] Received: 04 July 2017, Revised and Accepted: 16 August 2017 ABSTRACT Objective: The objective of the study was to compare the effect between alginate (Alg)-based raft-forming and Alg liquid on healing gastroesophageal reflux disease (GERD) and gastric ulcer in rats. Methods: Each of the 18 fasted rats was given 1 ml acidified pepsin. Then, rats were divided into three groups. Each group consisted of six rats. Group 1 (negative control) was orally given 1 ml distilled water, Group 2 was given 1 ml Alg-based raft-forming liquid, and Group 3 was given 1 ml Alg liquid. Then, the abdomen of rats was incised under anesthesia with ketamine, and then both their pylorus and the forestomach were ligated to form gastric reflux. After 4 hrs, all rats were killed with chloroform and their esophagus and stomach were examined macroscopically and microscopically (histopathology). Results: On macroscopic observation, all of the Group 1 rats (negative control) showed esophageal lesions and gastric lesions. Four rats of Group 2 (given Alg-based raft-forming) showed no esophageal lesion and two more rats showed a slight lesion, but all of the tested rats showed gastric lesions.
    [Show full text]
  • RAFT FORMING SYSTEM a REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Journal of Drug Delivery and Therapeutics (JDDT) Bhavsar et al Journal of Drug Delivery & Therapeutics; 2012, 2(5), 123-128 123 Available online at http://jddtonline.info REVIEW ARTICLE ADVANCES IN GRDDS: RAFT FORMING SYSTEM A REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C. Sini Surendran, Shah Viral H, Upadhyay UM Dept. of pharmaceutics, Sigma Institute of Pharmacy, Bakrol, Vadodara(Gujarat), India *Corresponding Author’s Ph: +91-9725512814, Email id: [email protected] Received 06 June 2012; Review Completed 26 Aug 2012; Accepted 26 Aug 2012, Available online 15 Sep 2012 ABSTRACT: In recent years several advancements has been made in research and development of Gastro retentive drug delivery system to overcome the drawback of non-site specificity when drug administered orally. In order to understand various physiological difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention time. We have reviewed various gastro retentive approaches designed and developed until now i.e. floating drug dosage systems (FDDS), swelling or expanding systems, mucoadhesive systems, high density system, Raft forming system, magnetic systems. Among these systems, the review summarizes the special focus on raft forming approach which comes under floating drug delivery system. Raft system incorporates alginate gels which have carbonate components react with gastric acid causes bubbles and this enables floating. Finally, Evaluation, advantages, disadvantages, future potential and marketed preparation of raft forming approach in gastro retentive drug delivery systems were covered. Key words-Advances in GRDDS, Raft forming system, alginic acid, gaviscon, INTRODUCTION: Conventional oral delivery is widely used in 4) Drugs with a narrow window of absorption E.g.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Cell Surface Mobility of GABAB Receptors Saad Bin
    Cell surface mobility of GABAB receptors Saad Bin Hannan September 2011 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy of the University College London Department of Neuroscience, Physiology, and Pharmacology University College London Gower Street London WC1E 6BT UK Declaration ii ‘I, Saad Hannan confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' ____________________ Saad Hannan September 2011 To Ammu, Abbu, Polu Abstract ivi Abstract Type-B γ-aminobutyric acid receptors (GABABRs) are important for mediating slow inhibition in the central nervous system and the kinetics of their internalisation and lateral mobility will be a major determinant of their signalling efficacy. Functional GABABRs require R1 and R2 subunit co-assembly, but how heterodimerisation affects the trafficking kinetics of GABABRs is unknown. Here, an α- bungarotoxin binding site (BBS) was inserted into the N-terminus of R2 to monitor receptor mobility in live cells. GABABRs are internalised via clathrin- and dynamin- dependent pathways and recruited to endosomes. By mutating the BBS, a new technique was developed to differentially track R1a and R2 simultaneously, revealing the subunits internalise as heteromers and that R2 dominantly-affects constitutive internalisation of GABABRs. Notably, the internalisation profile of R1aR2 heteromers, but not R1a homomers devoid of their ER retention motif (R1ASA), is similar to R2 homomers in heterologous systems. The internalisation of R1aASA was slowed to that of R2 by mutating a di-leucine motif in the R1 C-terminus, indicating a new role for heterodimerisation, whereby R2 subunits slow the internalization of surface GABABRs.
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
    [Show full text]
  • Poster Session III, December 6, 2017
    Neuropsychopharmacology (2017) 42, S476–S652 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org Poster Session III a high-resolution research tomograph (HRRT), and struc- Palm Springs, California, December 3–7, 2017 tural (T1) MRI using a 3-Tesla scanner. PET data analyses were carried out using the validated 2-tissue compartment Sponsorship Statement: Publication of this supplement is model to determine the total volume of distribution (VT) of sponsored by the ACNP. [18F]FEPPA. Individual contributor disclosures may be found within the Results: Results show significant inverse associations (con- abstracts. Part 1: All Financial Involvement with a pharma- trolling for rs6971 genotype) between neuroinflammation ceutical or biotechnology company, a company providing (VTs) and cortical thickness in the right medial prefrontal clinical assessment, scientific, or medical products or compa- cortex [r = -.562, p = .029] and the left dorsolateral nies doing business with or proposing to do business with prefrontal cortex [r = -.629, p = .012](p values are not ACNP over past 2 years (Calendar Years 2014–Present); Part 2: corrected for multiple comparisons). No significant associa- Income Sources & Equity of $10,000 per year or greater tions were found with surface area. (Calendar Years 2014 - Present): List those financial relation- Conclusions: These results, while preliminary, suggest links ships which are listed in part one and have a value greater than between the microglial activation/neuroinflammation and $10,000 per year, OR financial holdings that are listed in part cortical thickness in the dorsolateral prefrontal cortex and one and have a value of $10,000 or greater as of the date of medial prefrontal cortex in AD patients.
    [Show full text]